GT Biopharma (GTBP) AI Stock Analysis

• Market Cap: $5.96M
• Dividend Yield: N/A
• Average Volume (3M): 936.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: N/A
• EPS Growth: -26.02%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -7.02
• Shares Outstanding: 2,536,397
• 10 Day Avg. Volume: 15,721
• 30 Day Avg. Volume: 936,668
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $11.00
• Price Target Upside: 368.09% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

GT Biopharma's overall score is significantly undermined by its poor financial performance, characterized by zero revenue and continuous losses. The precarious financial position and reliance on external funding are critical risks. Technical indicators show a stable but uninspiring trend, providing little support to the stock's outlook. Additionally, the negative P/E ratio and lack of dividends further diminish valuation appeal. The combination of these factors results in a low overall score, highlighting the company's need for strategic improvements.

GT Biopharma Business Overview & Revenue Model

Company Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

How the Company Makes Money

GT Biopharma makes money primarily through the development and commercialization of its proprietary TriKE platform, which is designed to create targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its product candidates upon regulatory approval. Key revenue streams include milestone payments, royalties on sales, and collaboration agreements with larger pharmaceutical companies. Additionally, GT Biopharma may receive funding from government grants and research collaborations to support its clinical trials and research initiatives.

GT Biopharma Financial Statement Overview

Summary

GT Biopharma's financial position is precarious, with zero revenue and continuous losses indicating an urgent need for product development or strategic partnerships. The negative equity and reliance on financing highlight financial vulnerabilities, while the persistent cash outflows from operations necessitate a focus on achieving operational efficiencies or securing further investment.

Income Statement

GT Biopharma has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company faces substantial operating losses, as evidenced by the negative EBIT and net income figures across all periods. This lack of revenue growth and persistent losses are significant concerns for the company's financial health.

Balance Sheet

The company has a negative stockholders' equity in recent years, indicating more liabilities than assets, which is a critical warning sign. However, the absence of debt in the latest period reduces financial risk. The low asset base and negative equity position suggest financial instability and potential solvency issues.

Cash Flow

GT Biopharma's operating cash flow has been consistently negative, reflecting ongoing cash burn without incoming revenue. However, the company has managed to maintain liquidity through financing activities, as seen in positive cash flow from financing. The inability to generate free cash flow further underscores the company's dependence on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-14.36M	-13.58M	-21.26M	-57.52M	-6.76M
	EBITDA
-14.36M	5.98M	-20.96M	-57.48M	-24.98M
	Net Income Common Stockholders
-13.16M	-7.60M	-20.50M	-58.69M	-31.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.95M	13.97M	16.51M	31.98M	5.30M
	Total Assets
4.23M	14.11M	16.74M	32.17M	5.66M
	Total Debt
0.00	58.00K	174.00K	31.00K	26.33M
	Net Debt
-3.95M	-1.02M	-5.50M	-8.94M	21.04M
	Total Liabilities
5.90M	6.63M	5.00M	10.26M	35.09M
	Stockholders Equity
-1.67M	7.48M	11.73M	21.91M	-29.26M
Cash Flow		Free Cash Flow
-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
	Operating Cash Flow
-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
	Investing Cash Flow
12.89M	-2.01M	12.14M	-23.04M	0.00
	Financing Cash Flow
2.98M	6.27M	-224.00K	42.32M	12.53M

GT Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.35
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Negative. The current price of 2.35 is below the 20-day moving average (MA) of 2.39, above the 50-day MA of 2.29, and below the 200-day MA of 2.50, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 50.43 is Neutral, neither overbought nor oversold. The STOCH value of 42.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GTBP.

GT Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMP	50 Neutral	$223.81M	―	-31.16%	―	―	15.17%
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
ADAP	46 Neutral	$66.06M	―	-273.36%	―	194.23%	45.50%
CRSP	46 Neutral	$2.81B	―	-19.20%	―	-89.95%	-123.71%
CLDX	43 Neutral	$1.05B	―	-26.84%	―	1.99%	15.95%
FATE	42 Neutral	$86.28M	―	-54.21%	―	-78.55%	-0.92%
GTBP	26 Underperform	$5.96M	―	-453.39%	―	―	-26.02%